Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice by unknown
VARIABLE CAPACITY OF L3T4+ T CELLS TO CAUSE
LETHAL GRAFT-VERSUS-HOST DISEASE ACROSS MINOR
HISTOCOMPATIBILITY BARRIERS IN MICE
From *The Wistar Institute ofAnatomy and Biology, Philadelphia, Pennsylvania 19104; and
the $Department ofImmunology, Scripps Clinic and Research Foundation,
La Jolla, California 92037
The transfer ofunprimedT cells to lethally irradiated allogeneic mice express-
ing multiple minor histocompatibility (H)' antigen differences can result in a
high incidence of lethal graft-versus-host disease (GVHD) (1-4) . Whichparticular
T cell subsets are responsible for causing GVHD to minorH differences is the
subject of controversy . Earlier studies using in vivo negative selection techniques
indicated that H-2K/D-restricted T cells caused GVHD to minorH differences ;
H-21-restricted T cells failed to elicit GVHD, and the presence of these cells did
not seem to be essential for the function of H-2K/D-restricted T cells (5, 6) .
Phenotyping studies with antibody and complement (C) supported the notion
that only Lyt-2+ and not Lyt-1+,2
- T cells caused minor H GVHD (6) . In
addition, Lyt-2+ cytotoxic T lymphocytes (CTL) with antirecipient minor H
specificity could be isolated from mice during the development ofGVHD (7) .
Recent reports, however, have indicated that Lyt-1+,2- or L3T4+ T cells can
cause GVHD across a full MHC barrier (8-10), especially when class II differ-
ences are involved (10) . Furthermore, in studies using highly purified T cell
subsets, GVHD directed to allo-class II differences was controlled solely by
L3T4+ cells, whereas GVHD to class I differences involved only Lyt-2+ and not
L3T4+ cells (11) .
In view of our prior finding that GVHD to minor H antigen differences
appeared to be caused solely by Lyt-2+ and not L3T4+ cells, the possibility arises
that GVHD following HLA-matched bone marrow transplantation in man could
be abolished by selectively depleting the marrow ofCD8+ cells . Because the data
on the identity of T cells causingGVHD to non-H-2 differences in mice is based
largely on a single strain combination (CBA --* B10.BR) and with T cells that
were only semipurified, we considered it important to reinvestigate this question
with a number of minor H-different strain combinations and to use highly
purified T cell subsets for GVHD induction .
In this study we have surveyed six different H-2-compatible, multiple minor
H antigen-different strain combinations for the ability of purified L3T4+ or
This work was supported by grants CA-38951 and AI-21687 from theU.S . Public Health Service .
'Abbreviations used in this paper:
￿
ATBM, anti-Thy-1 + C-treated bone marrow ; ATX, thymec-
tomized ; BSS, buffered saline solution ; H, histocompatibility ; LN, lymphnode ;MST, median survival
time .
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Lyt-2+T cells to cause lethal GVHD . In four of six of these combinations, lethal
GVHD appeared to be caused almost entirely by Lyt-2' cells, death in recipients
of L3T4+ cells being quite low even when presensitized cells were injected . In
the remaining two combinations, however, either L3T4+ or Lyt-2+ T cells were
able to cause a high incidence ofGVHD . These data suggest that the inability of
L3T4' cells to cause GVHD to minor H differences is not an invariable finding .
Materials and Methods
Mice.
￿
C3H .SW/Snj, C57BL/6J (B6), B10.D2/oSnj, DBA/2J, B10.BR/SgSnj, CBA/J,
BALB/cJ, and SJL/J mice were purchased from The Jackson Laboratory, Bar Harbor,
ME . B10.S mice were originally acquired from the Scripps Clinic and Research Founda-
tion, La Jolla, CA, and bred in our own colony . All mice were males, except SJL, and
used experimentally as cell donors and irradiated recipients between 8 and 16 wk of age .
Media.
￿
Bufferedsaline solution (BSS) supplemented with 0.1% BSA (Hyclone, Logan,
UT) was used for all in vitro manipulations of donor bone marrow cells and lymphocytes .
Final suspensions of cells for injection were prepared in BSS only .
Injections .
￿
All cell suspensions were given intravenously via the tail vein in a volume
of 0.5 ml .
Irradiation.
￿
A Shepherd Mark I 's'Cs irradiator (75 rad/min) was used for irradiating
mice .
Monoclonal Antibodies .
￿
Ascites fluid for anti-L3T4 [GK1 .5, rat IgG2a, and RL172, rat
IgM (12)], anti-Lyt-2 (3 .168, rat IgM), anti-Thy-1 .2 (Jlj, rat IgM), and anti-B (J1 Id, rat
IgM), mAb and guinea pig serum as a source of C were prepared and used as described
previously (13) . Anti-Lgp100 [30-C7 rat IgG2a (14), culture supernatant] mAb was used
for chimera phenotyping . Biotin-conjugated anti-L3T4(GK1 .5), anti-Lyt-2, and anti-Thy-
1 .2 were prepared with biotin succinimide ester (Vector Laboratories, Burlingame, CA) .
Purification of T Cell Subsets.
￿
In a modification of a technique described in detail
elsewhere (13), purified T cell subsets were obtained by treating pooled lymph node (LN)
cells with mAb plus C, followed by positive panning on antibody-coated petri plates . To
prepare Lyt-2+ cells, LN cells were treated with a mixture of anti-B (J11d) and anti-L3T4
(RL172) mAb plus C, washed, and then incubated on ice with anti-Lyt-2 (3 .168) mAb for
30 min . Cells were washed again and allowed to adhere to a plate coated with goat anti-
rat IgM Ab (Cooper Biomedical, Malvern, PA) for 1 h at 4 °C . After gentle but extensive
washing of nonadherent cells from the plates, the adherent cells were eluted by vigorous
pipetting. The eluted cells were routinely tested for phenotype and contained no detect-
able L3T4+ cells . An analogous procedure was used to prepare pure L3T4+ cells, i.e .,
pretreatment of LN cells with JI Id and anti-Lyt-2 mAb plus C, followed by positive
panning on anti-L3T4 (GK1 .5)-coated plates .
Phenotyping.
￿
Antibody-mediated lysis in the presence ofC was measured in a one-step
trypan blue exclusion assay . For fluorescent analysis with an Ortho 50H Cytofluorograf,
0.5 X 10 6 cells were labeled with appropriate biotin-conjugated mAb for 30 min at 4°C,
washed, and incubated for 10 min with FITC-conjugated avidin DCS (Vector Laborato-
ries), and washed three more times before use . The level ofFITC excitation and forward
and right-angle scatter were determined relative to unlabeled control cells . A similar
procedure was used for analysis of chimerism with anti-Lgp100 mAb and FITC-goat
anti-rat IgG, Fc portion-specific (Cooper Biomedical) secondary labeling .
Mortality Assayfor GVHD .
￿
As described previously (1), 2- to 4-mo-old recipient mice
were exposed to a midlethal dose of irradiation (750-820 rad), and then ^-6 h later were
injected intravenously with a mixture of T cell-depleted donor bone marrow (anti-Thy-
1 + C-treated bone marrow [ATBM] ; 4 X 106 viable cells) together with the purified T
cell subsets . Recipients ofATBM cells alone served as controls . Mice were given food and
water ad libitum and were checked routinely for morbidity and mortality, Experiments
were terminated after 80 d . Median survival times (MST) were calculated for pooled
experiments as previously described (10), and statistical comparisons between groups
made by the Mann-Whitney two-sample rank test .1554
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TABLE I
Surface Markers ofLyt-2+ and L3T4+ T Cell Subsets Purified From C3H.SWLN Cells
Group
￿
Pretreatment ofC3H.SW
LN* Assay for typing cells*
WholeT
￿
JI Id (anti-B cell) + C'
L3T4+ ￿JI Id + anti-Lyt-2 + C' ;
pan on anti-L3T4 plate
I-yt-2+
￿
JI Id+ anti-L3T4 + C' ;
anti-Lyt-2 alone; pan on
goat anti-rat IgM plate
* For purification and phenotyping procedures, see Materials and Methods .
Percentage of
cells positive for :
L3T4 Lyt-2
Presensitization of Donor Cells.
￿
6-wk-old C3H.SW mice were thymectomized (ATX)
and injected intraperitoneally 2 wk later with 2X 106 B6 spleen cells. They were used as
LN donors for the GVHD assay 3 wk after immunization, at which time they were also
tested for the generation of secondary anti-minor H CTL responses . Cellswere cultured
(4 X 106 cells/well of a Costar 24-well plate) with an equal number of irradiated (1,500
rad) B6 spleen stimulator cells for 7 d at 37 ° C, 8% C0 2. Cells were then tested for
cytotoxic activity in microtiter plates against Cry` labeled 2-d-old Con A blast cells in a
standard 4 h release assay . The percent specific release was determined relative to
spontaneous and maximum release controls .
In Vitro Proliferation .
￿
Aliquots of2 X 105 responder LN L3T4+ cells, purified by the
procedures described above, were cultured in flat-bottom microtiter plates with 8 X 105
irradiated (2000 rad) spleen cells as stimulators in a volume of 200 Al, and then pulsed
with 0.25 uCi [5H]TdR 18 h before harvest (13) .
Results
Preparation of T Cell Subsets .
￿
In all of the experiments presented below,
pooled LN cells from appropriate donor mice ( five to eight mice depending
upon the particular strain) were prepared by a combination of antibody plus C
depletion and panning techniques (see Materials and Methods) to obtain purified
T cell subsets . Every preparation of cells was phenotyped by cytofluorescent
analysis using a biotin-antibody-FITC-avidin system . A typical example of the
results that are obtained with the purification procedure is shown in Table I, in
which C3H.SW cells are analyzed by both antibody cytotoxicity and FITC
staining . Treatment of normal C3H.SW LN cells with JI Id mAb plus C alone
yielded a B-depleted population containing an approximately 2:1 ratio of L3T4+
to Lyt-2' cells (Group A) ; with B6 mice and the B10 H-2 congenic lines, the
ratio of L3T4+ to Lyt-2' cells approached 1 :1 (13) . LN cells treated with JI ld
and 3.168 (anti-Lyt-2) mAb plus C followed by positive panning for L3T4+ cells
(Group B) were >95% L3T4+ and contained no detectable Lyt-2+ cells by both
measures of analysis . Conversely, LN cells treated with J11d and RL172 (anti-
L3T4) mAb plus C and panned for Lyt-2'' cells (Group C) were 92-96% Lyt-2+
and appeared to be devoid of L3T4+ cells (the failure to observe 100% purity
Complement-mediated cytotoxic- 64 .2 33.0
ity 63.7 36.4
FACS- fluorescein-avidin
Complement-mediated cytotoxic- 96 .8 0.0
ity 95 .7 0.0
FACS-fluorescein-avidin
0 .0 96.4
0.0 92,8KORNGOLD AND SPRENT
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by FITC staining might have reflected interference by residual unlabeled anti-
body from the panning step).
GVHD Mortality Across Minor H Barriers with T Cell Subsets. The general
experimental approach was to irradiate recipient mice with 750-820 rad and, 6
h later, transfer a mixture of 4 X 106 donor anti-Thy-1 plus C-treated (T cell-
depleted) bone marrow (ATBM) along with either whole T cells (J1ld plus C
treated LN), purified L3T4+, or Lyt-2+ T cells; the dosage of T cells was kept
at 106 for all experiments. Six different H-2-compatible, minor H antigen-
disparate strain combinations were tested for the capacity of T cell subsets to
cause lethal GVHD: C3H.SW -+ B6 (Fig. 1 a); DBA/2 --* B10.D2 (Fig. I b);
BI0.BR --3- CBA (Fig. 1 c); B10.S --+ SJL (Fig. 1 d); B10.D2 --* DBA/2 (Fig. 1 e);
and B10.D2 --+ BALB/c (Fig. If). The individual minor H and other known
loci differences between donor and recipient, and the overall mortality rates are
summarized in Table 11. In viewing the results as a whole, the following points
should be noted.
First, the transfer of 106 whole T cells led to (a) late-onset GVHD in the
C3H.SW--+B6 combination, (b) minimal disease in the DBA/2 --* B10.D2 group,
and (c) severe GVHD in the remaining four strain combinations, with high
incidence and early onset (with a particularly acute GVHD response in the
B10.D2 --~, BALB/c group) .
Second, in three of the strain combinations (C3H.SW -+ B6, DBA/2
B10.D2, and B10.S --* SJL) the transfer of L3T4+ T cells was clearly ineffective
at mediating lethal GVHD. Except for a few mice, the recipients remained
healthy and did not exhibit any typical clinical symptoms of disease. A few late-
onset deaths occurred in the B10.BR --* CBA combination, suggesting a mild
incidence of GVHD. In two combinations, i.e., B10.D2 --3- DBA/2 and B10.D2
--* BALB/c, the L3T4+ cellswere able to induce a high incidence ofGVHD with
an MST only slightly greater than with transfer of whole T cells (45 vs. 38 d,
and 24 vs. 20 d, respectively).
Third, inall sixcombinations, Lyt-2+Tcells werecapable ofmediatingGVHD.
In the C3H.SW --+ B6 and DBA/2 --+ B10.D2 groups, Lyt-2'' cells appeared to
be more potent than whole T cells, possibly reflecting the two- to threefold
enrichment for Lyt-2+ T cells; in terms of MST, however, this difference was
not statistically significant. In the B10.BR --* CBA and B10.S --3. SJL strain
combinations, the incidence of GVHD and survival patterns were virtually the
same for the whole T cell and Lyt-2+ cell groups; the onset ofGVHD occurred
early in these two groups in comparison to the first two strain combinations . In
the B10.D2 --* DBA/2 and B10.D2 --* BALB/c groups, Lyt-2+ cells seemed to
be less potent than either whole T cells or L3T4' cells, as reflected by a lower
incidence of GVHD and a prolonged MST value; this difference was statistically
significant only in the B10.D2 --+ BALB/c combination.
GVHD with Preimmunized T Cell Subsets.
￿
Because the precursor frequency of
minor H antigen-specific L3T4+ cells is probably quite low in unprimed popu-
lations, it was of interest to determine whether primed L3T4+ cells might be
more potent mediators of lethal GVHD. Donor C3H.SW mice were first thy-
mectomized (ATX) to prevent the further influx of unprimed T cells into the
peripheral lymphoid organs; 2 wk later the mice were immunized intraperito-1556
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FIGURE 1 . Lethal GVHD in H-2-compatible multiple minor H antigen-different strain
combinations (a-f ). Recipient mice were irradiated and injected intravenously with 4 x 106
donor ATBM alone (long dash line) or along with 106 donor whole T cells (solid line), purified
L3T4+ cells (medium dash line), or Lyt-2+ cells (short dash line).
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TABLE II
Summary of GVHD Mortality after Transferring Purified TCell Subsets Along With ATBM to
Lethally Irradiated H-2-compatible Allogeneic Recipients
k By use of Mann-Whitney statistical analysis, significant differences (p < 0.01) were found for groups 12 vs. 13, 12 vs. 14, 13 vs. 14,
and 15 vs. 16, whereas no significance differences (p > 0.05) were observed for groups 1 vs. 2, 3 vs. 4, 5 vs. 6, 7 vs. 8, 9 vs. 10, 9
vs. 11, and 10 vs. 11.
TABLE III
Cytotoxic Activity ofAnti-minor H CTL Generatedfrom LN of Thymectomized C3H.SWMice
Immunized with B6 Spleen Cells
CTLwere generatedandassayed as describedin MaterialsandMethods.Why a lowprimaryresponse
wasobserved with the ATX C3H.SW mice but not with normal C3H.SW mice is obscure.
neally with 2 X 107 B6 spleen cells. After another 3 wk the recipients were
sacrificed, and their lymph nodes were pooled for T cell subset preparations.
Stimulation of unseparated lymph node cells with B6 spleen cells in culture led
to typical secondary CTL responses (Table III), indicating that, at least in the
case of CTL generation, the T cells were indeed primed. For GVHD induction,
the potency of whole T cells was appreciably higher with preimmunized cells
(82% incidence, MST of 37 d) (Fig. 2) than with unprimed cells (48% incidence,
MST of 58 d) (Fig. 1 a). Preimmunization increased the potency of Lyt-2+ cells
in terms of mortality rate (95% for primed cells, 73% for unprimed cells) but
had little effect on the MST (48 vs. 45 d). Preimmunization did cause a slight
increase in the mortality rate with L3T4+ cells, 5 of 25 mice dying between days
34 and 80, though none ofthe surviving mice exhibited any symptoms suggestive
ofchronic GVHD.
Extent ofHematopoietic Chimerism.
￿
To examine the extent ofdonor reconsti-
Donor
Strain H-2
Recipient
Strain
lrradi dia- a-
tion
Some ofthe known
genetic differences
between donor and
recipient
80-d Mortality (dead/total) and MST
transfer ofdonor cells:*
WholeT L3T4* T Lyt-2` T
(d)after
ATBM
alone
Unprimed: rad
C3H.SW H-2b B6 750 H-1,-3,-7,-8,-9,-l3 12/25 1/21 20/26 0/24
Mlsb, Ly-1,2 (58)' (>80) (45)s (>80)
DBA/2 H-2d BIO.D2 820 H-1,-3,4,-8,43 Mlsb, 6/23 3/26 16/22 2/25
Ly-1,2 (>80)s (>80) (53~ (>80)
BIO.BR H-2t CBA 750 H-l,3,7,8,9,12 23/24 6/17 23/24 2/24
Tla, Mlsd, Ly-1,2 (38)' (73) (39)s (>80)
BIOS H-2' SJL 800 H-1,-3,-7,-8,-9, 21/24 3/24 21/24 0/20
-12,43 Tla, Mls` (34)° (>80) (35)e (>80)
B10.132 H-2d DBA/2 800 H-l,3,4,8,13 Mls', 36/39 35/41 16/38 3/38
Ly-1,2 (38)9 (45) 10 (58)11 (>80)
B10.132 H-2d BALB/c 750 H-l,3,4,7,8,9,13 14/15 14/18 12/16 0/13
(20)1Y (24)° (39)14 (>80)
Primed:
C3H.SW H-2b B6 750 H-l,3,7,8,9,13 14/17 5/25 20/21 2/24
Mlsb, Ly-1,2 (37)" (>80) (48)16 (>80)
Responder LN group
Percent
25 .0:1
specific lysis
12.5:1
of B6
6.3:1
target cells
3.2:1
at E:T
1.6:1
ratios of.
0.8:1
Preimmunized ATX C3H.SW 71 58 44 31 21 10
ATX C3H.SW 18* 10 7 5 4 2
Preimmunized normal C3H.SW 83 78 60 41 25 13
Normal C3H.SW 0 0 0 0 0 11558
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FIGURE 2.
￿
Lethal GVHD in irradiated (750 rad) B6 mice injected intravenously with 4 X
10 6 C3H.SW ATBM alone or along with either 106 presensitized C3H.SW whole T cells,
purified L3T4' cells, or Lyt-2+ cells.
tution of irradiated B6 mice given either unprimed or preimmunized C3H.SW
L3T4' T cells plus donor ATBM, randomly selected mice were sampled after
80 d for lymphocyte expression of the Lgp100 determinant ; this marker is
expressed on a high proportion (>80%) of C3H.SW lymphocytes, but is not
expressed on B6 cells (Table IV). It is apparent from Table IV that all of the
mice tested showed near complete repopulation with donor-derived cells.
In Vitro Proliferation Responses ofL3T4+ Cells.
￿
In view ofthe surprising finding
that unprimed L3T4' cells caused acute GVHD in the B10.D2 --3- DBA/2 and
B10.D2 -* BALB/c groups, we examined the capacity of 1310.132 L3T4' cells to
mount primary proliferative responses to DBA/2 vs . BALB/c stimulators in vitro
in an assay involving all six of the donor-recipient combinations described above
(as shown in Table V) . It is apparent that L3T4' cells responded poorly, if at all,
in the C3H.SW anti-136, DBA/2 anti-1310 .132, B10.S anti-SJL, and 1310.132 anti-
BALB/c combinations ; anti-allo-H-2 control responses were strong . B10.BR
anti-CBA and B10.D2 anti-DBA/2 combinations gave high proliferative re-
sponses, but these responses were probably directed to Mls determinants (Mlsd
andMlsa beingstrongly stimulatory for unprimed T cells) . It is apparent therefore
that the ability of L3T4' T cells to proliferate in vitro does not correlate with
GVHD induction . The point to emphasize is that unprimed B10M L3T4' cells
caused severe GVHD in BALB/c mice yet gave virtually no proliferative response
to BALB/c in vitro .* LN cells from individual experimental mice were tested for the expression of the Lgp100
determinant by FACS analysis using secondary staining with FITC-conjugated goat anti-rat IgG
(Fc) antibody . The percent positive values are relative to the normal positive control .
KORNGOLD AND SPRENT
TABLE IV
Extent of Chimerism in Irradiated B6 Mice Transplanted with C3H.SWATBM Alone or
in Addition to C3H.SWL3T4+T Cells
TABLE V
Proliferation Responses ofL3T4+ T Cells From Donor Strains
1559
* See Table II for details of minorH antigens(MHA)and other known differences.
$ See Table 11 for mortality data .
Responder
strain
Stimulator
strain Stimulus*
[sH]Thymidine incorporation
on :
Day 4 Day 5 Day 6
Severity of
GVHD by
L3T4+ cells
cpm
C3H.SW C3H.SW - 925 613 1,286
B6 MHA+ Mlsb 636 1,063 1,570 Very weak
DBA/2 H-2d+MHA + Mls' 51,660 33,635 13,696
DBA/2 DBA/2 - 1,590 1,825 2,024
B10.D2 MHA+ Mlsb 797 679 1,005 Very weak
CBA H-2k + MHA + Mlsd 8,148 13,859 28,365
B10.BR B10.BR - 666 575 675
CBA MHA+ Mlsd 41,111 12,251 8,883 Weak
DBA/2 H-2d+MHA + Mls' 47,917 10,830 15,870
1310.S B10.S - 1,185 1,339 1,079
SJL MHA+ Mls` 408 393 376 Very weak
DBA/2 H-2d+MHA + Mls' 24,355 19,539 16,361
B10.D2 B10.D2 - 610 301 477
DBA/2 MHA+ Mls' 6,638 1,947 1,091 Strong
BALB/c MHA 759 833 832 Strong
CBA H-2" + MHA + Mlsd 22,002 36,399 18,644
Exp .
Priming of
donor L3T4+
cells
Donor group Percent of cells
positive for Lgp100*
Normal C3H.SW LN - 82.9
Normal B6 LN - 0.0
C3H.SW-* B6 - L3T4+ (a) 82.5
- L3T4+ (b) 82.6
ATBM (a) 96.5
ATBM (b) 84.8
ATBM (c) 96.7
C3H.SW --* B6 + L3T4+ (a) 95.2
+ L3T4+ (b) 100.1
+ L3T4+ (c) 94.2
ATBM (a) 83.5
ATBM (b) 87.81560
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Discussion
There are two main findings in this paper. First, highly purified populations
of Lyt-2+ cells caused a high incidence of lethal GVHD in all six H-2-compatible
minor H-different strain combinations tested . Second, the capacity of L3T4'
cells to cause GVHD across minorH barriers was highly variable : GVHD was
virtually absent in two strain combinations, weak in one combination, and very
strong in two other combinations .
The finding that purified Lyt-2+ cells were able to elicit GVHD to minor H
differences in the apparent absence ofL3T4'cells is consistent with our previous
finding that depleting T cells of la-restricted T cells or Lyt-l+ T cells failed to
inhibit GVHD (5, 6) . The data are also in line with the evidence that transfer of
purified Lyt-2' cells to heavily irradiated (1,100 rad) thymectomized mice (11)
or nude mice (15) leads to rejection ofH-2 class I-different skin allografts . These
and other data (13, 16-23) strongly suggest that, at least in certain situations,
Lyt-2+ cells are able to function in the apparent absence ofL3T4' cells, i.e ., cells
capable of producing exogenous help (IL-2) . It does not necessarily follow,
however, that the response of Lyt-2' cells is IL-2 independent. Lyt-2' cells
themselves are able to produce IL-2 (16-21), and it is quite possible that the
function of Lyt-2' cells at a population level depends upon IL-2 release from a
minor subset of helper-independent Lyt-2+ cells (22, 24). In support of this idea
it has been found that GVHD to minor H differences can be inhibited by
injection of anti-IL-2-R antibody (25) and that injection of IL-2 potentiates
GVHD directed to class I (but not class II) differences (9) .
Because the present experiments used only intermediate doses of irradiation
(750-820 rad ; higher doses led to unacceptable losses in the ATBM control
group), the possibility exists that IL-2 produced by radioresistant host L3T4'
cells provided significant levels of help for the injected Lyt-2+ cells . Even if host
L3T4' cells could be removed, e.g., by preconditioning the recipients with anti-
L3T4 antibody (26), there is still the objection that the "de novo" generation of
L3T4' cells from donor stem cells could lead to bystander IL-2 production . We
are currently investigating this possibility by using thymectomized mice as recip-
ients .
The limited capacity ofL3T4'T cells to causeGVHD across minorH barriers
in four of the six strain combinations tested is interesting in light of the finding
that L3T4' cells are very potent mediators ofGVHD directed to H-2 class II
differences but not to class I differences (11, 27, 28) ; by the same token, L3T4'
cells give high primary MLR only to class II and not to class I differences . Since
MLR to minor H differences are generally poor, one could argue that the
capacity of L3T4' cells to mediate GVHD is simply a reflection of precursor
frequency . In this respect we anticipated that the marked variability in the
capacity of L3T4' cells to mediate GVHD across minor H barriers would
correlate with primary proliferative responses to the non-H-2 differences in-
volved . No such correlation was found . For example, L3T4' cells gave high
MLR to strainsexpressing Mlsa (B10 .D2 -~-DBA/2)and Mlsd(B10.BR, CBA/J)
differences, but L3T4''-mediated GVHD was prominent in only one of these
two situations (BIO.D2 --* DBA/2) . Although Mls differences might potentiate
GVHD (29), the most intense form of L3T4+-mediated GVHD was seen in theKORNGOLD AND SPRENT
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B10.D2 -> BALB/c combination, i .e ., an Mls-identical combination . In the case
of MLR, however, B10.D2 L3T4+ cells gave virtually no response to BALB/c
stimulators, implying that primary proliferative responses in vitro are conspicu-
ously unhelpful in predicting the severity ofGVHD . It should be mentioned that
B. L. Hamilton (personal communication) has also seen a high incidence of
GVHD in irradiated BALB/c recipients of B10.D2 L3T4+ cells (anti-Lyt-2 + C-
treated spleen cells) .
In trying to account for the variable capacity of L3T4+ cells to mediate GVHD
across minor H barriers, it is of interest that certain minor H antigens are
immunodominant in terms of Lyt-2+ CTL recognition (30-33) . Similar immu-
nodominance might apply to L3T4+ cells . Thus it is conceivable that L3T4+
cells might be able to recognize only a very limited number ofminorH antigens,
perhaps far fewer than Lyt-2+ cells. If so, it is possible that only certain minor
H-different strain combinations, e.g ., B10.D2 -> BALB/c, display the particular
antigens that are immunogenic for L3T4+ cells. In this respect it is intriguing
that B10.D2 L3T4+ cells express high Ia-restricted CTL activity for BALB/c
target cells after priming in vivo followed by secondary stimulation in vitro in
the presence of IL-2 (34) . The obvious question is whether the intensity of
L3T4+CTL responses to minorH differences in vitro show any correlation with
the severity ofGVHD . We are currently investigating this possibility . We caution
that, at present, the nature of the target antigens for L3T4+-mediated GVHD
in the B10.D2 ---+ BALB/c and B10.D2 -* DBA/2 combinations is completely
unknown. Indeed, there is no direct evidence that the target antigens are minor
H antigens per se rather than other non-MHC antigens . It should also be stressed
that the crucial issue ofwhetherGVHD reflects CTL activity is still unsettled.
Because of the difficulty of preparing highly purified T cell subsets in large
numbers, relatively low doses ofT cells (106) were used in the present studies . It
could be argued, therefore, that in the three strain combinations in which L3T4+
cells failed to elicit GVHD to minorH differences, significantGVHD might have
been observed with higher doses of L3T4+ cells. Although we cannot rule out
this possibility, previous studies showed that even very high doses (2 X 10') of
anti-Lyt-2 + C-treated lymph node cells failed to elicit significant GVHD in the
CBA ---> B10.BR combination . Paradoxically, very high doses ofL3T4+ cells can
sometimes inhibit GVHD . Thus, whereas small doses (105-106) of B6 L3T4+
cells regularly cause close to 100% mortality in irradiated class II-differentbm 12
mice, doses of 2 X 107 L3T4+ cells often result in only low mortality rates (our
unpublished data) .
Defining which particular minorH antigens (or other non-MHC antigens) act
as GVHD targets for L3T4+ cells is of potential importance for HLA-matched
marrow transplantation in humans . On the basis of studies with the CBA -->
Bl0.BR combination (where L3T4+ cells did not cause GVHD) we suggested
previously that depleting marrow inocula of CD8+ (Lyt-2+ equivalent) cells but
leaving the CD4+ cells intact might be beneficial in terms of facilitating engraft-
ment and leading to rapid restoration of T-dependent antibody production (35) .
However, with the present appreciation that L3T4+ cellscan causesevere GVHD
to non-MHC differences in certain situations, the rationale for not depleting
human marrow ofCD4+ cells obviously needs to be reconsidered . An important1562
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goal in the future will be to devise methods for predicting whether CD4+ cells
are likely to be injurious to the HLA-matched recipient .
Summary
Highly purified populations ofL3T4+and Lyt-2+T cell subsets were compared
for their capacity to cause lethal GVHD in six different H-2-compatible, multiple
minor histocompatibility antigen-different murine strain combinations . In four
of these combinations (C3H.SW --). B6, DBA/2 --> B10.D2, BIO.BR -* CBA,
and BIOS --> SJL), lethal GVHD appeared to be caused almost entirely by Lyt-
2 + cells ; the injection of L3T4+ cells resulted in low mortality even when these
cells were presensitized to the recipient antigens . In the remaining two combi-
nations (B10.D2 --+ DBA/2 and B10 .D2 --* BALB/c), L3T4+ T cells were able
to cause a high incidence ofGVHD and were more potent than the Lyt-2'' cells .
The implications of these findings are discussed .
Receivedforpublication 22 December 1986 and in revisedform 17 February 1987.
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